Will Noxopharm get Traction from Endocyte Sale?

So the burning question is.... will the sale announcement of Endocyte to Novartis for the cash sum of US$2.1Billion have a knock on effect for us here at Noxopharm?

From the reports that I have read, Novartis made the offer primarily to acquire the 177 Lu-PSMA-617 technology that Endocyte currently has in a phase 3 registration study for metastatic castration-resistant prostate cancer. The study has 750 men on study in 80 centres in the USA, Canada and Europe.

The Endocyte trial has overall survival as the main endpoint, so it will still be a while before it’s finished.... most likely about 2 years away.  BUT.... if Novartis believes it’s worth $US 2.1 Billion right now.... that must tell us a great deal.

As you guys will already know, Noxopharm is  currently  embarked upon a study with St Vincent’s Hospital, Sydney, using Veyonda as a sensitising agent in conjunction with the same radioligand treatment 177 Lu-PSMA-617 treatment that Endocyte are using.

Just imagine if NOX can increase the efficiency or the efficacy of this radioligand to any usable degree ... then what would this technology of ours be worth to a company like Novartis??

The recent press release from NOX included the information that the study investigators had sought permission to double the number of patients from 16 to 32 in the absence of any safety issues to date. This was done so as to now provide a larger study size capable of delivering meaningful safety and efficacy endpoints.

Once they have completed the deal with Endocyte.... Novartis will surely be open to see if there is any other technology out there that can increase the value of their newly acquired treatment.

It looks like the market started to see the potential of this on Friday when the announcements started to sink in a little. It will be interesting to see what happens to our share price this week in light of the Novartis cash buy out.

Apples